Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash from Financing Activities (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Cash from Financing Activities for 3 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 108.32% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.4 million through Dec 2025, down 96.4% year-over-year, with the annual reading at $12.4 million for FY2025, 96.4% down from the prior year.
  • Cash from Financing Activities hit $4.3 million in Q4 2025 for Immunocore Holdings, up from $1.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $396.0 million in Q1 2024 to a low of -$51.5 million in Q4 2024.
  • Historically, Cash from Financing Activities has averaged $32.5 million across 3 years, with a median of $4.0 million in 2025.
  • Biggest YoY gain for Cash from Financing Activities was 6350.76% in 2024; the steepest drop was 923.65% in 2024.
  • Year by year, Cash from Financing Activities stood at $6.3 million in 2023, then plummeted by 923.65% to -$51.5 million in 2024, then surged by 108.32% to $4.3 million in 2025.
  • Business Quant data shows Cash from Financing Activities for IMCR at $4.3 million in Q4 2025, $1.9 million in Q3 2025, and $3.7 million in Q2 2025.